 To demonstrate that sarilumab monotherapy was superior to adalimumab monotherapy with respect to signs and symptoms as assessed by disease activity score 28 DAS28-erythrocyte sedimentation rate ESR in participants with active rheumatoid arthritis RA who were either intolerant of, or considered inappropriate candidates for continued treatment with methotrexate MTX, or after at least 12 weeks of continued treatment with MTX, were determined to be inadequate responders. 